Paul McBarron - 13 Dec 2021 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Role
E. VP, Fin, CFO, COO and Secretary, Director
Signature
/s/ Paul McBarron
Issuer symbol
CYCC
Transactions as of
13 Dec 2021
Net transactions value
$0
Form type
4
Filing time
15 Dec 2021, 15:19:10 UTC
Next filing
02 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYCC Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 13 Dec 2021 Common Stock 100,000 $3.45 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.
F2 These securities were granted as part of the Issuer's annual compensation review to executive officers.

Remarks:

E. VP, Fin, CFO, COO and Secretary